MIRA PHARMACEUTICALS, INC. Logo

MIRA PHARMACEUTICALS, INC.

Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.

MIRA | US

Overview

Corporate Details

ISIN(s):
US60458C1045
LEI:
Country:
United States of America
Address:
1200 BRICKELL AVENUE, 33131 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic and neuropsychiatric disorders. The company's pipeline is centered on two primary neuroscience programs. One program is developing Ketamir-2, a next-generation oral ketamine analog. The other is focused on a new molecular synthetic analog of THC (tetrahydrocannabinol). MIRA aims to address unmet medical needs by creating advanced, patent-protected treatment options for a range of central nervous system conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all MIRA PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MIRA PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MIRA PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
PLUS THERAPEUTICS, INC. Logo
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
United States of America PSTV
PMV Pharmaceuticals, Inc. Logo
Developing small molecule therapies targeting p53 mutations to treat cancer.
United States of America PMVP
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America PRPO

Talk to a Data Expert

Have a question? We'll get back to you promptly.